Abstract:More than 2·7 million individuals worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 187 000 have died from the resulting coronavirus disease 2019 (COVID-19) as of April 25, 2020.1WHOCoronavirus disease 2019 (COVID-19) situation report 96.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2Date: April 25, 2020Date accessed: April 26, 2020Google Scholar Despite the common use of immunosuppressive medications, it appears that patients with inflammatory bowel disease (IBD) have a similar risk for COVID-19 to the general population.2SECURE-IBDCOVID-19 in people with inflammatory bowel disease.https://ucalgary.maps.arcgis.com/apps/opsdashboard/index.html#/7f596bdbf4654e19a3a3cf13b6e597deDate accessed: April 26, 2020Google Scholar The management of IBD during and after the pandemic is challenging. The main concerns from a clinician's perspective are the risk for COVID-19 in patients with IBD (especially in those taking immunosuppressive medications or with malnutrition), timely follow-up and monitoring of disease, choice of and change in medical and surgical therapy, feasibility and availability of endoscopic assessment, and protection of health-care providers against SARS-CoV-2 infection.3Mao R Liang J Shen J et al.Implications of COVID-19 for patients with pre-existing digestive diseases.Lancet Gastroenterol Hepatol. 2020; 5: 426-428Summary Full Text Full Text PDF PubMed Scopus (247) Google Scholar, 4Yang H Zhu LR Tian D Inflammatory Bowel Disease GroupChinese Society of GastroenterologyChinese Medical AssociationManagement of patients with inflammatory bowel disease during epidemic of 2019 novel coronavirus pneumonia.Chin J Dig. 2020; 40 (in Chinese).: E001Google Scholar, 5International Organisation for the study of IBDIOIBD update on COVID19 for patients with Crohn's disease and ulcerative colitis.https://www.ioibd.org/ioibd-update-on-covid19-for-patients-withcrohns-disease-and-ulcerative-colitisDate: April 23, 2020Date accessed: April 23, 2020Google Scholar, 6Rubin DT Abreu MT Rai V Siegel CA Management of patients with Crohn's disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting.Gastroenterology. 2020; (published online April 6.)DOI:10.1053/j.gastro.2020.04.002Summary Full Text Full Text PDF Scopus (170) Google Scholar, 7Rubin DT Feuerstein JD Wang AY Cohen RD AGA clinical practice update on management of inflammatory bowel disease during the covid-19 pandemic: expert commentary.Gastroenterology. 2020; (published online April 10.)DOI:10.1053/j.gastro.2020.04.012Summary Full Text Full Text PDF Scopus (179) Google Scholar Additional concerns have been raised from the patients' perspective, including medical, psychosocial, and financial factors. Therefore, we did a survey involving patients with IBD to analyse their feedback on their care during the early and late phases of the COVID-19 outbreak in China. The anonymous questionnaire was designed by clinicians, registered nurses, and patient representatives and was posted on the China Crohn's and Colitis Foundation's patient portal. 2277 participants completed the survey. 880 (39%) were women and 1397 (61%) men; 1639 (72%) had Crohn's disease and 555 (24%) had ulcerative colitis. 111 (5%) respondents were from Hubei province. Of the 2277 respondents, 1134 (50%) were employed full or part time. Most (934 [82%] of 1134) had to work at home during the pandemic and 443 (39%) reported reduced income (appendix). More than 50% of the respondents reported some degree of mood changes, with the peak of the frequency of moderate-to-severe psychological change in the middle of the outbreak in China—ie, mid-February, 2020. Many (1331 [58%] of 2277) respondents were worried about the risk for SARS-CoV-2 infection for themselves and their family and more than half (1184 [52%]) were concerned about the difficulty in seeing physicians (appendix). Almost three-quarters of patients (1691 [74%]) reported that their disease state was stable during the initial outbreak (from January to March, 2020) and 1842 (81%) reported that their disease remained stable in the later phase (ie, mid-April, 2020). 137 (6%) patients were admitted for IBD flares and 23 (1%) had surgery. 639 (28%) patients used telemedicine—of whom 487 (76%) sought help from IBD health-care providers online—and 847 (37%) of 2277 patients had face-to-face visits. Most patients (1744 [77%]) did not change IBD medications during the outbreak. Of the 533 patients with a change in medications, the main reasons for the change were recommendations from treating physicians (157 [30%]), being unable to receive intravenous infusions (151 [28%]), and the availability of physicians or facilities (148 [28%]). Most respondents (1606 [71%] of 2277) were still able to obtain oral medications online (1125 [49%]) or from hospital pharmacies as before (481 [21%]). By mid-April, 2020, most (1628 [71%]) were able to obtain oral medicines from their hospital pharmacies as before (appendix). The COVID-19 pandemic has posed challenges to every aspect of respondents' lives. Measures to curtail the virus, such as shelter-in-place, government mandates for postponing elective procedures, restriction of transportation, and the reassignment of gastroenterologists or IBD health-care providers, can interfere with routine or emergent care. Most patients with IBD experienced stable disease during the early and current phases of the outbreak and those individuals did not have to change their medications. Our survey data suggest that the impact of the COVID-19 outbreak on medical management of IBD was largely related to logistics. Restructuring IBD care, such as personnel reassignment, infusion service availability, drug delivery, and telemedicine, have been proposed as being important for IBD management during such a pandemic.8Allocca M Fiorino G Furfaro F et al.Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.Clin Gastroenterol Hepatol. 2020; (published online April 15.)DOI:10.1016/j.cgh.2020.04.028Summary Full Text Full Text PDF PubMed Scopus (40) Google Scholar Our survey shows that a quarter of patients sought care via telemedicine with their IBD physicians. There was also increased use of online delivery of oral medications. Mental health issues have been reported by both patients and health-care providers during the outbreak.9Percudani M Corradin M Moreno M Indelicato A Vita A Mental health services in Lombardy during COVID-19 outbreak.Psychiatry Res. 2020; 288112980Crossref PubMed Scopus (105) Google Scholar, 10Zhang WR Wang K Yin L et al.Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China.Psychother Psychosom. 2020; (published online April 9.)DOI:10.1159/000507639Crossref Scopus (985) Google Scholar Mental health issues are particularly important in patients with diseases of long duration, such as IBD. Our survey suggests that although patients' moods were affected by concerns about psychosocial and economic issues, their disease course was not affected. Respondents were concerned about the risk of infection and worried about access to health care. More than 50% of respondents had mood changes and their mood changes appeared to improve as the pandemic trend was flattening. More than 80% of employed respondents had to work from home and 40% of the respondents reported a reduced income. The financial impact can be long lasting, which could affect the affordability of and adherence to medical care. This could eventually alter disease outcomes. The results from this large survey suggest that the COVID-19 pandemic affects patients with IBD medically, psychosocially, and financially. Most respondents' disease remained stable. Respondents using maintenance therapy and those requiring medication adjustments because of disease flares often met logistical challenges. The availability of telemedicine and online drug delivery services might have eased some of the burden. Psychosocial and economic effects of the pandemic on IBD care are common. The long-lasting effects will need to be studied over time. FAF has served as a consultant for Bristol-Myers Squibb, Braintree Labs, Gilead, GlaxoSmithKline, Innovation Pharmaceuticals, Janssen, Pfizer, and Sebela, and sits on a data safety monitoring board for Lilly and Theravance. CNB has served on advisory boards for AbbVie Canada, Roche Canada, Janssen Canada, Takeda Canada, and Pfizer Canada; has been a consultant for Mylan Pharmaceuticals; and has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; and acted as a speaker for Janssen Canada, AbbVie Canada, Medtronic Canada, and Takeda Canada. BS has served as a consultant and speaker for AbbVie, Janssen, and Takeda. YC, SH, HW, J-JZ, and RPK declare no competing interests. The authors are grateful to support from surveyed patients. The study was approved by the ethics committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). YC, SH, and HW contributed equally to this Comment. Download .pdf (.43 MB) Help with pdf files Supplementary appendix

Zhigang Liu,Kaixing Le,Xin Zhou,James L Alexander,Simeng Lin,Claire Bewshea,Neil Chanchlani,Rachel Nice,Timothy J McDonald,Christopher A Lamb,Shaji Sebastian,Klaartje Kok,Charlie W Lees,Ailsa L Hart,Richard C Pollok,Rosemary J Boyton,Daniel M Altmann,Katrina M Pollock,James R Goodhand,Nicholas A Kennedy,Tariq Ahmad,Nick Powell,Madiha Islam,Nick Croft,Bessie Cipriano,Caroline Francia,Nosheen Khalid,Ashley Kingston,Irish Lee,Anouk Lehmann,Kinnari Naik,Kevin Samuels,Nicolene Plaatjies,Hafiza Khatun,Farjana Bokth,Elise Pabriaga,Rebecca Saich,Hayley Cousins,Wendy Fraser,Rachel Thomas,Matthew Brown,Benjamin White,Nikolaos Kirkineziadis,Bernadette Tilley,Pennie Porter,Rachel Bryant,Natalia Robaczewska,Rafeeq Muhammed,Rehana Bi,Catherine Cotter,Jayne Grove,Kate Hong,Ruth Howman,Monica Mitchell,Sophie Clayton,Louise Rogers,Sugrah Sultan,Melanie Rooney,Charlotte Cottrill,Salil Singh,Chris Dawe,Robert Hull,Natalie Silva,Julie Chadwick,Laura Robertson,Jonathan Manning,Lauren Finlayson,Allison Roebuck,Joy Dawson,Sunil Sonwalkar,Naomi Chambers,Matthew Robinson,Andrew Haigh,Lear Matapure,Tim Raine,Varun George,Christina Kapizioni,Konstantina Strongili,Tina Thompson,Mohamed Ahmed,Christos Kontos,Claire Dawson,Christophe Bourges,Isabella Barbutti,Megan E Gozzard,Philip Hendy,Rhian Bull,Patricia Costa,Lisa Davey,Hayley Hannington,Kribashnie Nundlall,Catarina Martins,Laura Avanzi,Jaime Carungcong,Sabrina Barr,Richard Appleby,Emma Johnson,Eathar Shakweh,Kath Phillis,Rachel Gascoyne,Amanda Crowder,Amanda Whileman,Ian London,Jenny Grounds,Emmeline Martin,Susie Pajak,Jude Price,Kathryn Cawley,Sandra Powell,Nichola Kearsley,Anjan Dhar,Ellen Brown,Amanda Cowton,Kimberley Stamp,Ben Warner,Carmel Stuart,Louise Lacey,Shanika de Silva,Clare Allcock,Philip Harvey,Lesley Jones,Elise Cooke,Jayne Slater,Dominic King,Johanne Brooks,Pearl Baker,Hannah Beadle,Carina Cruz,Debbie Potter,Joe Collum,Farzana Masters,Aashish Kumar,Samantha Coetzee,Mihaela Peiu,Becky Icke,Jill Williams,Meena Raj,Edward Gaynor,Sibongile Chadokufa,Bonita Huggett,Hamza Meghari,Sara El-Khouly,Fevronia Kiparissi,Waffa Girshab,Lynda Russell-Walker,Christopher Jackson,Sara Sidler,Andrew Claridge,Emily Fowler,Laura McCafferty,Lesley Haxton,Peter Irving,Karolina Christodoulides,Angela Clifford,Patrick Dawson,Sailish Honap,Samuel Lim,Raphael Luber,Karina Mahiouz,Susanna Meade,Parizade Raymode,Rebecca Reynolds,Anna Stanton,Sherill Tripoli,Naomi Hare,Sopuluchukwu Odukwe,Senthuran Balachandran,Emma North,Jessica North,Bria Browne,Jessica Cordle,Ella Jameson,Yih Harn Siaw,Lane Manzano,Jonathan Segal,Ibrahim Al-Bakir,Imran Khakoo,Sofiya Portukhay,Nora Thoua,Katherine Davidson,Jagrul Miah,Lisa Canclini,Alex Hall,Hassina Furreed,Christine Mitchell-Inwang,Melony Hayes,Sally Myers,Alison Talbot,Jack Turnbull,Emma Whitehead,Katie Stamp,Alison Pattinson,Verghese Mathew,Leanne Sherris,Julie Wilcox,Sankaranarayanan Ramachandran,Hayley Robertson,Angela Harvey,Lucy Hicks,Tara-Marie Byrne,Leilani Cabreros,Hannah Downing-Wood,Sophie Hunter,Mohammad Aamir Saifuddin,Hemanth Prabhudev,Sharmili Balarajah,Jan Krucznski,Kalliopi Driva,Andrea D'Mello,Parith Shah,Rocio Castro-Seoane,Hajir Ibraheim,Laura E Constable,Jonathan W Lo,Melissa Torkizadeh,Sherine K Hermangild,Helen Sutherland,Elva Wilhelmsen,Katherine Mackintosh,Ajay M Verma,Juliemol Sebastian,Mohammad Farhad Peerally,Parizade Raymode,Anne-marie Guerdette,Susan Coburn,Ching Yee Novem lam,Donna Durrant,Belinda Schaefer,Solange Serna,Muhammad Shahzad,Alexandra Kent,Lee Meng Choong,Benedetta Pantaloni,Pantelis Ravdas,Babu Vadamalayan,Stephen Foley,Becky Arnold,Cheryl Heeley,Wayne Lovegrove,Donna Sowton,Lynne Allsop,Heidi Gregory,Mandy Gill,Megan Holmes,Valeria Balan,Susan Smith,Sarah Turner,Philip J Smith,Alan Steel,Giovanna Bretland,Sarah King,Martina Lofthouse,Lindsey Rigby,Sreedhar Subramanian,David Tyrer,Kate Martin,Christopher Probert,Nikolaos Kamperidis,Temi Adedoyin,Manisha Baden,Jeannette Brown,Feba Chacko,Lisa Young,Michela Cicchetti,Mohammad Saifuddin,Priya Yesupatham,Rohit Gowda,Maureen Williams,Karen Kemp,Rima Akhand,Glaxy Gray,Anu John,Maya John,Tasnim Mohammed,Diamond Sathe,Natasha Jones,Jennifer Soren,Michael Sprakes,Julie Burton,Patricia Kane,Stephanie Lupton,Jacqueline Bartholomew,Elizabeth Denis,Alison Daniels,George MacFaul,Diane Scaletta,Loria Siamia,Felicity Williams,Chloe Green,Zeljka Ver,Chris Lamb,Mary Doona,Ashleigh Hogg,Lesley Jeffrey,Andrew King,R Alexander Speight,Jennifer Doyle,Ruth Owen,Jenny Haworth,Linda Patterson,Vithusa Varnaulasingam,Craig Mowat,Debbie Rice,Susan MacFarlane,Anne MacLeod,Samera Mohammed,Shona Murray,Anne Elliott,Mary Anne Morris,Louise Coke,Grace Hindle,Eirini Kolokouri,Catherine Wright,Claire Lee,Nicola Ward,Adele Dann,Melanie Lockett,Charlotte Cranfield,Louise Jennings,Ankur Srivastava,Lana Ward,Nouf Jeynes,Poonam Ranga,Praveen Rajasekhar,Lisa Gallagher,Jill Ward,Rae Basnett,Judy Murphy,Lauren Parking,Emma Lawson,Stacey Short,David Devadason,Gordon Moran,Neelam Khan,Lauren Tarr,Charmaine Olivia,Samantha Warbarton,Sian Kelly,Jimmy Limdi,Kay Goulden,Asad Javed,Lauren McKenzie,Julie Melville,Eleanor Liu,Joseph Sabine,Patricia Jacob,Denise McSorland,Nick Schofield,Lisa Cornwall,James Quirke,Emma Crook,Anne Turner,Pradeep Bhandari,Michelle Baker-Moffatt,Joanne Dash,Alison Le Poidevin,Hayley Downe,Lucille Bombeo,Helen Blackman,Rebecca Smith,Alan Wiles,Hannah Bloxham,Jose Dias,Evelyn Nadar,Hollie Curgenven,Ellie Gilham,Jonathan Macdonald,Shona Finan,Faye McMeeken,Misbah Mahmood,Stephanie Shields,John Paul Seenan,Des DeSilva,Susanna Malkakorpi,Rachel Carson,Holly Lawrence,Ofori Boateng,Felix Kpodo,Simon Whiteoak,Kelli Edger-Earley,Luke Vamplew,Joanna Samways,Sue Roffe,Sarah Ingram,Joel James,Sharon Botfield,Fiona Hammonds,Clare James,Zoe Berry,Gemma Aspinall,Sarah Hawkins,Marian Parkinson,Helen Gardner-Thorpe,Suzie Marriott,Clare Redstone,Halina Windak,Ana-Marie Adam,Hannah Mabb,Emma Stevenson,Jessica Record,Charles Murray,Cynthia Diaba,Fexy Joseph,Glykeria Pakou,Yvonne Gleeson,Annalyn Nunag,James Berrill,Natalie Stroud,Carla Pothecary,Lisa Roche,Keri Turner,Lisa Deering,Lynda Israel,Evelyn Baker,Maxine Nash,Andrew Fagbemi,Felicia Jennings,Imelda Mayor,Jill Wilson,Alice Wheeler,Nicola Phillips,John Gordon,Emma Levell,Silvia Zagalo,Ina Hoad,Bindu Anil,Richard Russell,Paul Henderson,Margaret Millar,Christopher Alexakis,Natalia Michalak,Cheryl Marriott,Sarah Stone,Veronika Pristopan,John Saunders,Helen Burton,Vanessa Cambridge,Tonia Clark,Charlotte Ekblad,Sarah Hierons,Joyce Katebe,Emma Saunsbury,Rachel Perry,Matthew Brookes,Kathryn Davies,Marie Green,Ann Plumbe,Clare Ormerod,Helen Christensen,Hannah Howlett,Anne Keen,Jonathan Ogor,Marie Greenhaigh,Karen Knowles,Shanzi Yin,Maria Poulaka,Alpha Anthony,Emily Newitt,Fiona Trim,Ruth Casey,Katherine Seymour,Catherine Reed,Lijo Joy,Edward Fogden,Kalisha Russell,Samia Hussain,Anne Phillips,Muaad Abdulla,Jeff Butterworth,Colene Adams,Mandy Carnahan,Elizabeth Buckingham,Danielle Childs,Alison Magness,Jo Stickley,Nichola Motherwell,Louise Tonks,Hannah Gibson,Kate Wistance,Caradog Thomas,Elaine Brinkworth,Lynda Connor,Amanda Cook,Tabitha Rees,Rachel Harford,Sean Farley,Marie Jones,Emma Wesley,Alison Moss,Jacob Lucas,Claire Lorimer,Maria Oleary,Maxine Dixon,Fiona Goodchild,Rebecca Twenlow,Corinne Pawley,Arvind Ramadas,Julie Tregonning,Olaku Okeke,Wendy Jackson,Ioannis Koumoutsos,Viji George,Swapna Kunhunny,Sophie Laverick,Isla Anderson,Sophie Smith,Joan Joyce,Sarala Janarthan,Kamal Patel,Mariam Ali,Hilda Mhandu,Aleem Rana,Katherine Spears,Joana Teixeira,Mark Mencias,Abigail Seaward,Jessica Sousa,Nooria Said,Mark Soomaroo,Valentina Raspa,Asha Tacouri,Nicholas Reps,Rebecca Martin,Tinashe Samakomva,Christian Selinger,Jenelyn Carbonell,Felicia Onovira,Doris Quartey,Alice L'Anson,Andrew Ashworth,Jessica Bailey,Angie Dunn,Gjuzel Bespaloi,Harold Rasalan,Zahid Mahmood,Racheal Campbell,Liane Marsh,Tricia Coughlan,Wisam Jafar,Janet Marrs,Christopher McPheat,Monira Rahman,Sarah Davies,Ruth Habibi,Ellen Jessup-Dunton,Teishel Joefield,Reina Layug,Vinod Patel,Joanne Vere,Victoria Turner,Susan Kilroy,Martina Coulding,Martyn Clark,Jacqueline McCormick,Attiya Nisar,Gareth Walker,Stacey Atkins,Jasmine Growdon,Becky George,Charlotte McNeill,Bryony Reed,Angela Foulds,Catherine Marshall,Michele Allison,Briony Dillon,Rachel Cooney,Lillie Bennett,Louise Bowlas,Sharafaath Shariff,Aileen Fraser,Dwayne Punnette,Rebecca Lambert,Charlotte Bishop-Hurman,Elizabeth Undrell,Katherine Belfield,Said Din,Catherine Addleton,Marie Appleby,Johanna Brown,Kathleen Holding,Catherine Fraser,Janice Birkenshaw,Jodie Williams,Kamille Maulion,Meg Lane,Arita Kravale,Claud Smith,Patricia Hooper,John deCaestecker,Olivia Watchorn,Ellie Clarke,Chris Hayward,Susan Inniss,Lucy Pritchard,Karen Rudge,Amanda Carney,Sarah Griffee,Jervoise Andreyev,Sathish Babu,Caroline Hayhurst,Carol Lockwood,Lynn Osborne,Amanda Roper,Karen Warner,Julia Hindle,Tara Lawrence,Kimberley Netherton,Caroline Watt,Kinga Szymiczek,Shameer Mehta,James Bell,William Blad,Lisa Whitley,Roman Jastrub,Dhamaraj Durai,Mark Baker,Elizabeth John Sivamurugan,Mim Evans,Fraser Cummings,Clare Harris,Amy Jones,Liga Krauze,Sohail Rahmany,Michelle Earl,Jenny Vowles,Audrey Torokwa,Mirela Petrova,Andrew Procter,Jo Stanley,Claudia Silvamoniz,Marion Bettey,Amar Wahid,Zoe Morrison,Rhian Thomas-Turner,Louise Yendle,Jennifer Muller,Marcus Mitchell,John Kirkwood,Anna Barnes,Rakesh Chaudhary,Melanie Claridge,Chiara Ellis,Cheryl Kemp,Ogwa Tobi,Jentus Milton,Emma Johnston,Metod Oblak,Carmen Winpenny,Marie-Louise Svensson,Jo Godden,Marium Ashhar,Debbie Alexander,Kate Covil,Lauranne Derikx,Sryros Siakavellas,Helen Baxter,Scott Robertson,Linda Smith,Beena Poulose,Anne Colemam,Margareta Balint,Gareth Rhys-Jones,Helen Watters,Susan Begg,Beatriz Grosalcalde,Judy Coyle,Kerrie Johns,Rachel Hughes,Janet Phipps,Abigail Taylor,Catherine MacPhee,Suzanne Brooks,Jolene John,Michelle Edwards,Katie Smith,Linda Howard,Dianne Wood,Ajay Muddu,Laura Barman,Janine Mallinson,Tania Neale,Diana Ionita,Kerry Elliot,Alison Turnball,Iola Thomas,Alice Thomas,Kelly Andrews,Jonathon Sutton,Caroline Mulvaney Jones,Julia Roberts,Jeannie Bishop

Abstract:BACKGROUND: Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutralising antibodies against highly transmissible omicron (B.1.1.529) BA.1, and BA.4 and BA.5 (hereafter BA.4/5) SARS-CoV-2 variants, which possess the ability to evade host immunity and, together with emerging sublineages, are now the dominating variants causing current waves of infection.METHODS: CLARITY IBD is a prospective, multicentre, observational cohort study investigating the effect of infliximab and vedolizumab on SARS-CoV-2 infection and vaccination in patients with inflammatory bowel disease (IBD). Patients aged 5 years and older with a diagnosis of IBD and being treated with infliximab or vedolizumab for 6 weeks or longer were recruited from infusion units at 92 hospitals in the UK. In this analysis, we included participants who had received uninterrupted biological therapy since recruitment and without a previous SARS-CoV-2 infection. The primary outcome was neutralising antibody responses against SARS-CoV-2 wild-type and omicron subvariants BA.1 and BA.4/5 after three doses of SARS-CoV-2 vaccine. We constructed Cox proportional hazards models to investigate the risk of breakthrough infection in relation to neutralising antibody titres. The study is registered with the ISRCTN registry, ISRCTN45176516, and is closed to accrual.FINDINGS: Between Sept 22 and Dec 23, 2020, 7224 patients with IBD were recruited to the CLARITY IBD study, of whom 1288 had no previous SARS-CoV-2 infection after three doses of SARS-CoV-2 vaccine and were established on either infliximab (n=871) or vedolizumab (n=417) and included in this study (median age was 46·1 years [IQR 33·6-58·2], 610 [47·4%] were female, 671 [52·1%] were male, 1209 [93·9%] were White, and 46 [3·6%] were Asian). After three doses of SARS-CoV-2 vaccine, 50% neutralising titres (NT50s) were significantly lower in patients treated with infliximab than in those treated with vedolizumab, against wild-type (geometric mean 2062 [95% CI 1720-2473] vs 3440 [2939-4026]; p<0·0001), BA.1 (107·3 [86·40-133·2] vs 648·9 [523·5-804·5]; p<0·0001), and BA.4/5 (40·63 [31·99-51·60] vs 223·0 [183·1-271·4]; p<0·0001) variants. Breakthrough infection was significantly more frequent in patients treated with infliximab (119 [13·7%; 95% CI 11·5-16·2] of 871) than in those treated with vedolizumab (29 [7·0% [4·8-10·0] of 417; p=0·00040). Cox proportional hazards models of time to breakthrough infection after the third dose of vaccine showed infliximab treatment to be associated with a higher hazard risk than treatment with vedolizumab (hazard ratio [HR] 1·71 [95% CI 1·08-2·71]; p=0·022). Among participants who had a breakthrough infection, we found that higher neutralising antibody titres against BA.4/5 were associated with a lower hazard risk and, hence, a longer time to breakthrough infection (HR 0·87 [0·79-0·95]; p=0·0028).INTERPRETATION: Our findings underline the importance of continued SARS-CoV-2 vaccination programmes, including second-generation bivalent vaccines, especially in patient subgroups where vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapies.FUNDING: Royal Devon University Healthcare NHS Foundation Trust; Hull University Teaching Hospital NHS Trust; NIHR Imperial Biomedical Research Centre; Crohn's and Colitis UK; Guts UK; National Core Studies Immunity Programme, UK Research and Innovation; and unrestricted educational grants from F Hoffmann-La Roche, Biogen, Celltrion Healthcare, Takeda, and Galapagos.

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

Patterns of Care for Inflammatory Bowel Disease in China During the COVID-19 Pandemic.

Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice

Outcomes Following Vascular and Endovascular Procedures Performed During the First COVID-19 Pandemic Wave

The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Global Impact of the First Coronavirus Disease 2019 (COVID-19) Pandemic Wave on Vascular Services

Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study

Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges

Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set

Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China

Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Life in lockdown: experiences of patients with IBD during COVID-19

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY

P1155 Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19